CHARLES K. WOLFE JR., M.D.; MARK H. LEPPER, M.D.; ESTON R. CALDWELL JR., M.D.; HAROLD W. SPIES, M.D.; HARRY F. DOWLING, M.D., F.A.C.P.
During the last few years the appearance of several agents effective in the treatment of bacterial pulmonary infections has diminished the frequency of nontuberculous pleural space infection.1 This condition still occurs, however, as a complication of some pneumonias, particularly in patients with a virulent infection in whom treatment has been delayed.2
Two features of the pleural cavity contribute toward making therapy of infections of the pleura more difficult than that of infections in many other sites. First, the ability of different drugs to pass into a collection of fluid or pus is quite variable; hence the question of whether the
WOLFE CK, LEPPER MH, CALDWELL ER, SPIES HW, DOWLING HF. TREATMENT OF NONTUBERCULOUS BACTERIAL PLEURAL SPACE INFECTIONS WITH AUREOMYCIN: RESULTS OF TREATMENT IN NINE PATIENTS; CONCENTRATION OF AUREOMYCIN IN PLEURAL AND PERICARDIAL FLUID IN SEVEN PATIENTS(TREATMENT OF NONTUBERCULOUS BACTERIAL PLEURAL SPACE INFECTIONS WITH AUREOMYCIN: RESULTS OF TREATMENT IN NINE PATIENTS; CONCENTRATION OF AUREOMYCIN IN PLEURAL AND PERICARDIAL FLUID IN SEVEN PATIENTS*). Ann Intern Med. 1952;37:164–171. doi: 10.7326/0003-4819-37-1-164
Download citation file:
Published: Ann Intern Med. 1952;37(1):164-171.
Cardiology, Infectious Disease, Pericardial Disease, Pulmonary/Critical Care.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use